

Outcome of the first Medicines Utilisation Research in Africa Group meeting to promote sustainable and rational medicine use in Africa

First MURIA Group Workshop and Symposium, University of Botswana, Gaborone, Botswana 27th to 29th July 2015

Amos Massele¹, Johanita Burger², Norah L Katende-Kyenda³, Francis Kalemeera⁴, Thatoyaone Kenaope^{5,6}, Dan Kibuule⁴, Ogochukwu Mbach⁷, Mwangana Mubita⁴, Margaret Oluke⁸, Adedunni Olusanya⁹, Bene D Anand Paramadhas^{5,10}, Pauline van Zyl¹¹, *Brian Godman^{12,13}

¹Department of Clinical Pharmacology, School of Medicine, University of Botswana, Gaborone, Botswana. Email: amos.massele@mopipi.ub.bw

²Medicine Usage in South Africa (MUSA), Faculty of Health Sciences, School of Pharmacy, North-West University, Potchefstroom, South Africa. Email: johanita.burger@nwu.ac.za

³Department of General Medicine and Therapeutics, Walter Sisulu University, University in Mthatha, Unitha, South Africa. Email: nkyenda1@gmail.com

⁴School of Pharmacy, University of Namibia, Windhoek, Namibia. Email: fkalemeera@unam.na, dkibuule@unam.na, mmubita@unam.na

⁵Drug Utilisation Research Unit (DURU), Nelson Mandela Metropolitan University, South Africa

⁶Nyangabwe Hospital, Botswana. Email: kenaopethato@gmail.com, anandbene@yahoo.com

⁷Rex & Nhlanguano Pharmacy, Mbabane, Swaziland. Email: ogombachu@yahoo.com

Department of Pharmacology and Pharmacognosy, School of Pharmacy, University of Nairobi, Nairobi, Kenya. Email: olukamarga@yahoo.com

⁹Babcock University Teaching Hospital, Ilisan-Remo, Ogun state, Nigeria. Email: dedunolusanya@gmail.com

¹⁰University of South Africa, Pretoria, South Africa

¹¹University of the Free State, Nelson Mandela Drive, Bloemfontein, South Africa. Email: vzylpm@ufs.ac.za

¹²Department of Laboratory Medicine, Division of Clinical Pharmacology, Karolinska Institutet, Karolinska University Hospital Huddinge, SE-141 86, Stockholm, Sweden. Email:

Brian.Godman@ki.se

¹³Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, UK. Email: Brian.godman@strath.ac.uk

*Author for correspondence

(Accepted for publication in Expert Review Pharmacoeconomics and Outcomes Research – Please keep CONFIDENTIAL)

Abstract

The first MURIA (Medicines Utilisation Research in Africa) group workshop and symposium brought researchers together from across Africa to improve their knowledge on drug utilisation (DU) methodologies as well as exchange ideas. As a result, progress DU research to formulate future strategies to enhance the rational use of medicines. Anti-infectives was the principal theme for the one day symposium following the workshops. This included presentations on the inappropriate use of antibiotics as well as ways to address this. Concerns with adverse drug reactions and adherence to anti-retroviral medicines was also discussed, with poor adherence remaining a challenge. There were also concerns with the underutilisation of generics. These discussions resulted in a number of agreed activities before the next conference in 2016.

Key words: Rational use of medicines, antibiotics, drug utilisation, Africa, ARVs

Manuscript

MURIA is a multidisciplinary research group striving to promote sustainable, rational medicine use in Africa (1). Activities include the first MURIA workshop and symposium held at the University of Botswana from 27th to 29th July 2015 (1). This was opened by the Deputy Vice Chancellor of Academic Affairs (Prof Totolo) and the Minister of Health, Hon Dorcas Makgato. Hon Dorcas Makgato

emphasised the importance of addressing the potential misuse of antibiotics as well as critically looking at antiretroviral (ARV) medicines, non-communicable diseases (NCDs) and generic medicines. Anti-infectives and NCDs are also of particular importance globally. She stressed that we can only act on data, facilitated by cross-national studies.

Delegates subsequently attended either introductory or advanced workshops. Ilse Truter opened the Introductory Group workshop by giving an outline of key issues for drug utilisation (DU) research including guidelines, types of research, data sources and classification systems (2, 3) as well as giving examples. Margaret Oluka expanded on this by discussing the Anatomical Therapeutic Chemical /Defined Daily Dose (ATC/DDD) classification in more detail including DDDs/ 1000 inhabitants/ day (DIDs) to assess DU across countries. Olayinka Ogunleye discussed developing standardised indicators, which included together with goals: (i) average number of medicines prescribed/ patient encounter (<2), (ii) % medicines prescribed by generic name (close to 100%); (iii) % encounters prescribed an antibiotic (<30%); (iv) % encounters with an injection prescribed (<10%); (v) % medicines prescribed from an essential medicines list (EML) or formulary (close to 100%).

Brian Godman closed the morning session by discussing ways to influence the rational use of medicines, broken down into the 4Es – education, economics, engineering and enforcement (4). Multiple measures have enhanced the prescribing of generic versus patented statins, ACEIs versus patented angiotensin receptor blockers (ARBs), and generic versus patented ARBs (5, 6) as well as reduced antibiotic utilisation (7). Day one for the Introductory Group ended with Marike Cockeran discussing basic statistics applied to DU research.

Andy Gray open the Advanced Group workshop by discussing key issues concerning antibiotic DU research, with potential alternatives including DDDs/ 100 bed days/ unit of time and DDDs/ 100 patient encounters/ unit of time (8). Potential data sources vary by country, and include both private and public sectors as well as data from surveys (9). Matthias Adorka subsequently discussed novel approaches to DU research including developing new methodologies to assess appropriate antibiotic prescribing (10). Brent Knoesen then discussed key principles involved with undertaking qualitative research, including when it should be undertaken and potential applications in DU research.

Challenges for cross-national studies include using standard utilisation methods, the same protocol, robust datasets, working with health authorities to accurately document country measures and ensuring a good mix of countries and interventions to enhance future learnings (5, 6, 11). Johanita Burger discussed pharmacoconomics including the four basic study approaches alongside examples. Finally, Theunis Kotze ended the first day by discussing advanced statistical methods.

Day two for the Introductory Group started with Rianda Joubert discussing applications of DU research including quantitative and qualitative studies, e.g. questionnaires among physicians in Namibia ascertained first-line treatment of patients with upper respiratory tract infections (URTIs) was typically amoxicillin with clavulanic acid and ciprofloxacin for urinary tract infections (UTIs), against recommended Namibian guidelines (12). Household surveys are also an important source of DU data in Africa, especially where there is appreciable self-purchasing of medicines (13). Finally Andy Gray discussed the basic principles of medical and research ethics including the need for ethics in research, basic biomedical research principles, informed consent, the need for transparency as well as the challenges involved in retrospective and epidemiological research.

Lars Gustafsson started the second morning for the Advanced Group by exploring drug safety and the use of databases in DU research, especially with limited knowledge about adverse drug reactions (ADRs) in a number of countries (14). Examples include early warning indicators for HIV drug resistance (15), the use of open source clinical trials software systems (16), and the comprehensive longitudinal database regarding HIV therapy and its outcome in Botswana during the past decade (17). Interdisciplinary groups working together analysing, communicating their findings and follow-up DU in practice are all important considerations for changing prescribing behaviour. This is seen in Stockholm, Sweden, with high adherence rates to the 'Wise List' through a comprehensive approach and physician trust in those developing the formulary of just over 200 medicines in ambulatory care (18). The advanced workshop ended with Joseph Fadare leading discussions regarding ethics, especially key issues and challenges. This was illustrated with examples (19).

Anti-infectives were the principal theme of the oral and poster sessions for the symposium. A qualitative study among households in Kampala revealed the common cold was the most prevalent acute respiratory infection. There was high use of antibiotics at 43% of cases, mainly amoxicillin and cotrimoxazole, before seeking medical care, with a strong correlation between antibiotic use, presence of pneumonia symptoms, level of education of the caregiver and the source of medicines. Johanita Burger presented findings from a study conducted by Agyakwa and colleagues, who found high prescribing of fluoroquinolones by physicians in the private healthcare sector in South Africa, representing 28% of all antibiotic prescriptions (20). Qualitative research undertaken by Thatoyaone Kenaope and colleagues found among pharmacists in South Africa, the socio-economic status of patients, patient satisfaction, their knowledge of antibiotic indications and the professional relationship between healthcare professionals influenced physician prescribing behaviour. Consequently, there is a need to target all stakeholder groups to improve antibiotic use.

The irrational use of antibiotics was also seen among government facilities in Swaziland, with respiratory tract infections as the most common diagnosis. This led to suggestions that the government should strengthen hospital drugs and therapeutic committees as well as antibiotic management programmes. A retrospective study carried out by Bene Paramadhas and Tennyson Mgutshini among HIV-infected patients at a tertiary care facility in Botswana revealed a high degree of empiric prescribing with culture and sensitivity tests rarely ordered. There was a high degree of IV antibiotics prescribed at 52% of prescriptions, with only a limited number switched to oral medicines. Positively, all antibiotics prescribed were on the Botswana EML, and 86% of all antibiotics were prescribed by their generic name. Further studies and interventions are planned to address concerns. There are also plans in Botswana to undertake DU studies among private physicians treating patients for URTIs following the publication of national guidelines in 2012. This will form the basis of future measures.

Mwanga Mubita and colleagues found the implementation of a multifaceted antimicrobial care approach around 'Start smart, then focus' in an Internal Medicine ward at a University Teaching Hospital in Zambia led to improvements in the quality of antimicrobial prescribing in terms of compliance with the outlined care elements. Multifaceted approaches have also worked in other countries (7).

There are also concerns regarding ADRs and adherence to ARVs. Francis Kalemeera and colleagues using Namibia's Adverse Reporting database – VigiFlow® – ascertained that a nevirapine safety signal was detected after shifting the initiation of nevirapine to patients with higher CD4-counts than previously recommended. This resulted in the Ministry of Health in Namibia halting this move, demonstrating that locally derived ADR data can protect patients. This is important as the characteristics of patients with HIV in Africa are different from those in Europe and the US.

Razia Gaida discussed a systematic review of efavirenz and its side-effects that she and colleagues had undertaken (21). They found a total of 13 articles between 2001 and 2014, and concluded that as efavirenz does not commonly induce severe side-effects that warrant discontinuation, it can be considered for use in psychiatric patients.

Poor adherence remains a major challenge in patients, especially those on highly active antiretroviral therapy (HAART). Contributing factors include ADRs with HAART, high tablet count (typically >4) and lower earnings as discussed by Norah Katende. Current adherence rates to ARVs are also being followed up in Botswana following national guidelines changing ARV eligibility to better plan for the future.

There were also presentations on other disease areas. Pauline van Zyl undertook a study to examine the prevalence and co-morbidity of irritable bowel syndrome (IBS), depression and anxiety amongst retirement village residents in South Africa using a variety of questionnaires. Overall, there was a lower than expected rate of IBS. However, the majority of participants using antidepressants, anxiolytics and PPIs were taking these for one year or longer, with participants taking PPIs or antidepressants more likely to experience IBS symptoms.

Adedunni Olusanya assessed the effects of co-administration of other drugs on compliance, ADRs and seizure control in patients taking carbamazepine monotherapy for epilepsy. She found that

compliance was significantly lower in patients co-administered with other medicines; however, there was no significant difference in seizure control or reports of ADRs. Studies showed there are concerns with generic medicines in a number of African countries. Joseph Fadare and colleagues in Nigeria identified a number of gaps in physician perception of generics and their prescribing and dispensing. Margaret Oluka found prescribing of generics was sub-optimal at only 52% of prescriptions in an outpatient department of a national referral hospital in Kenya. Both need to be addressed before key stakeholders benefit from low cost generics.

Finally, there are ongoing initiatives to progress collaboration between centres in Africa through simplifying processes, thereby strengthening both capacity for drug development and RUM in Africa (22).

The feedback from the meeting was positive with attendees typically finding workshop presenters knowledgeable in their areas, with the content relevant to their needs. In addition, the information could be applied to their workplace. The main criticism was not enough time to debate key issues and their implications.

A number of activities are planned for 2015/ 2016, and we look forward to the second MURIA Group meeting in Botswana in July 2016.

All abstracts, workshop presentations including planned projects in 2015/ 2016 and the speech by the Minister of Health can be found on: <http://muria.nmmu.ac.za/Botswana-Workshop-and-Symposium-27-29-July-2015>. MURIA membership forms can be found on: <http://muria.nmmu.ac.za/Membership>.

Acknowledgements and financial disclosure

We would like to thank University of Botswana for the use of their excellent facilities, the administration team at UB for greatly facilitating all aspects of the workshop as well as IUPHAR, Botswana Public Officers' Medical Aid Scheme (BPOMAS) and the Ministry of Health for their sponsorship. This meeting was also in part supported by a VR-Link grant from Swedish Research Council (VR-Link 2013-6710) to Amos Y Masele and Lars L Gustafsson.

There are no conflicts of interest from any author.

References

1. Masele A, Godman B, Adorka M, Fadare J, Gray A, Lubbe M, et al. Initiative to progress research on medicine utilization in Africa: formation of the Medicines Utilization Research in Africa group. *Expert review of pharmacoeconomics & outcomes research*. 2015;15(4):607-10.
2. Wettermark B. The intriguing future of pharmacoepidemiology. *European journal of clinical pharmacology*. 2013;69 Suppl 1:43-51.
3. Truter I. A review of drug utilisation studies and methodologies. *Jordan Jn Pharmaceutical Sciences*. 2008;1(2):91-104.
4. Wettermark B, Godman B, Jacobsson B, Haaijer-Ruskamp FM. Soft regulations in pharmaceutical policy making: an overview of current approaches and their consequences. *Applied health economics and health policy*. 2009;7(3):137-47.
5. Godman B, Wettermark B, van Woerkom M, Fraeyman J, Alvarez-Madrado S, Berg C, et al. Multiple policies to enhance prescribing efficiency for established medicines in Europe with a particular focus on demand-side measures: findings and future implications. *Frontiers in pharmacology*. 2014;5:106.
6. Moon J, Godman B, Petzold M, Alvarez-Madrado S, Bennett K, Bishop I, Bucsecs A, Hesse U, Martin A, Simoens S, Zara C, Malmstrom RE. Different initiatives across Europe to enhance losartan utilisation post generics: impact and implications *Frontiers in pharmacology*. 2014;5(Article 219):1-10.

7. Furst J, Cizman M, Mrak J, Kos D, Campbell S, Coenen S, et al. The influence of a sustained multifaceted approach to improve antibiotic prescribing in Slovenia during the past decade: findings and implications. *Expert review of anti-infective therapy*. 2015;13(2):279-89.
8. WHO Collaborating Centre for Drug Statistics Methodology . Guidelines for ATC classification and DDD assignment 2015. Available at URL:http://www.whocc.no/filearchive/publications/2015_guidelines.pdf.
9. Holloway K, Mathai E, Gray A. Surveillance of community antimicrobial use in resource-constrained settings--experience from five pilot projects. *Tropical medicine & international health : TM & IH*. 2011;16(2):152-61.
10. Adorka M, Mitonga HK, Lubbe M, Serfontein J, Allen K. Assessment of the appropriateness of antibiotic prescriptions in Lesotho public hospitals: a novel methodology based on principles of antibiotic prescribing. *Journal of Public Health in Africa* 2014;5(354).
11. Cacace M, Ettelt S, Mays N, Nolte E. Assessing quality in cross-country comparisons of health systems and policies: towards a set of generic quality criteria. *Health policy (Amsterdam, Netherlands)*. 2013;112(1-2):156-62.
12. Pereko D, Lubbe S, Essack S. Antibiotic use in Namibia: prescriber practices for common community infections. *South African Family Practice*. 2015;1(1):1-5.
13. Eriksen J, Nsimba SE, Minzi OM, Sanga AJ, Petzold M, Gustafsson LL, et al. Adoption of the new antimalarial drug policy in Tanzania--a cross-sectional study in the community. *Tropical medicine & international health : TM & IH*. 2005;10(10):1038-46.
14. Tumwikirize WA, Ogwal-Okeng JW, Vernby A, Anokbonggo WW, Gustafsson LL, Lundborg SC. Adverse drug reactions in patients admitted on internal medicine wards in a district and regional hospital in Uganda. *African health sciences*. 2011;11(1):72-8.
15. Dube NM, Tint KS, Summers RS. Early warning indicators for HIV drug resistance in adults in South Africa at 2 pilot sites, 2008-2010. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America*. 2014;58(11):1607-14.
16. Ngari MM, Waithira N, Chilengi R, Njuguna P, Lang T, Fegan G. Experience of using an open source clinical trials data management software system in Kenya. *BMC research notes*. 2014;7:845.
17. Farahani M, Vable A, Lebelonyane R, Seipone K, Anderson M, Avalos A, et al. Outcomes of the Botswana national HIV/AIDS treatment programme from 2002 to 2010: a longitudinal analysis. *The Lancet Global health*. 2014;2(1):e44-50.
18. Bjorkhem-Bergman L, Andersen-Karlsson E, Laing R, Diogene E, Melien O, Jirlow M, et al. Interface management of pharmacotherapy. Joint hospital and primary care drug recommendations. *European journal of clinical pharmacology*. 2013;69 Suppl 1:73-8.
19. Fadare JO, Agboola SM, Opeke OA, Alabi RA. Prescription pattern and prevalence of potentially inappropriate medications among elderly patients in a Nigerian rural tertiary hospital. *Therapeutics and clinical risk management*. 2013;6:115-20.
20. Agyakwa WE, Lubbe MS, Burger JR, Katende-Kayenda NL, Cockeran M, Malik M. Fluoroquinolone prescribing patterns in the private healthcare sector of South Africa, 2005-2012. In Press *Latin American Journal of Pharmacy*.
21. Gaida R TI, Grobler C. Efavirenz: A review of the epidemiology, severity and management of neuropsychiatric side effects. In Press *South African Journal of Psychiatry*.
22. African Grid Science Gateway. Pharmacology Science Gateway initiative. Available at URL: <http://sgw.africa-grid.org/pharmacology-science-gateway>.